Log in

Relevant bibliographies by topics / Antitumour / Journal articles

To see the other types of publications on this topic, follow the link: Antitumour.

Journal articles on the topic 'Antitumour'

Author: Grafiati

Published: 4 June 2021

Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antitumour.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Asche, C. "Antitumour Quinones." Mini-Reviews in Medicinal Chemistry 5, no. 5 (May 1, 2005): 449–67. http://dx.doi.org/10.2174/1389557053765556.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Demeunynck, Martine. "Antitumour acridines." Expert Opinion on Therapeutic Patents 14, no. 1 (January 2004): 55–70. http://dx.doi.org/10.1517/13543776.14.1.55.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Slack, J. A., and C. Goddard. "Antitumour imidazotetrazines." Journal of Chromatography B: Biomedical Sciences and Applications 337 (January 1985): 178–81. http://dx.doi.org/10.1016/0378-4347(85)80027-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sreco-Zelenovic, Bojana, Sanja Grabez, Mirjana Popsavin, Vesna Kojic, Jovana Francuz, and Velimir Popsavin. "Synthesis and antiproliferative activity of simplified goniofufurone analogues." Journal of the Serbian Chemical Society, no. 00 (2020): 56. http://dx.doi.org/10.2298/jsc200730056s.

Full text

Abstract:

Several (+)-goniofufurone analogues with simplified structures were designed, synthesized and evaluated for their in vitro antitumour activity against a panel of human tumour cell lines. Dephenylated compounds 2 and 3, demonstrated remarkable antitumour activities, in the cultures of K562 and Raji cells with IC50 values in the range of 3.0-9.3 nM. Each of goniofufurone analogues lacking the tetrahydrofuran ring (4, 5 and 6) strongly inhibited the growth of at least one malignant cell line, with IC50 values in the range of 11-30 nM. Brief SAR analysis showed that the simplified goniofufurone analogues, designed by removing the phenyl group from C-7, or by opening the THF ring, could show stronger antiproliferative effects compared to control molecules. It is noticeable that analogues 2-8 are completely inactive with respect to the normal MRC-5 cell line. These findings, together with their potent antitumor activities, provide a suitable basis for the development of new and selective antitumour drugs.

APA, Harvard, Vancouver, ISO, and other styles

5

Jones, Bryony. "Evading antitumour immunity." Nature Reviews Cancer 16, no. 7 (June 17, 2016): 410. http://dx.doi.org/10.1038/nrc.2016.65.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Jones, Bryony. "Evading antitumour immunity." Nature Reviews Genetics 17, no. 7 (June 6, 2016): 374. http://dx.doi.org/10.1038/nrg.2016.77.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Mitra, Roshni, Sarvjeet Singh, and Ashok Khar. "Antitumour immune responses." Expert Reviews in Molecular Medicine 5, no. 3 (January 13, 2003): 1–22. http://dx.doi.org/10.1017/s1462399403005623.

Full text

Abstract:

The role of the immune system in combating tumour progression has been studied extensively. The two branches of the immune response – humoral and cell-mediated – act both independently and in concert to combat tumour progression, the success of which depends on the immunogenicity of the tumour cells. The immune system discriminates between transformed cells and normal cells by virtue of the presence of unique antigens on tumour cells. Despite this, the immune system is not always able to detect and kill cancerous cells because neoplasms have also evolved various strategies to escape immune surveillance. Attempts are being made to trigger the immune system into an early and efficient response against malignant cells, and various therapeutic modalities are being developed to enhance the strength of the immune response against tumours. This review aims to elucidate the tumouricidal role of various components of the immune system, including macrophages, lymphocytes, dendritic cells and complement.

APA, Harvard, Vancouver, ISO, and other styles

8

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 8, no. 1 (January 2003): 47–50. http://dx.doi.org/10.1016/s1359-6446(02)02551-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 8, no. 5 (March 2003): 229–31. http://dx.doi.org/10.1016/s1359-6446(03)02622-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Westwell, A. "Novel antitumour molecules." Drug Discovery Today 8, no. 9 (May 1, 2003): 421–22. http://dx.doi.org/10.1016/s1359-6446(03)02676-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 8, no. 15 (August 2003): 718–19. http://dx.doi.org/10.1016/s1359-6446(03)02776-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 8, no. 20 (October 2003): 955–57. http://dx.doi.org/10.1016/s1359-6446(03)02834-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Westwell, Andrew. "Novel antitumour molecules." Drug Discovery Today 6, no. 4 (February 2001): 215–16. http://dx.doi.org/10.1016/s1359-6446(00)01619-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Westwell, Andrew. "Novel antitumour molecules." Drug Discovery Today 6, no. 9 (May 2001): 489–91. http://dx.doi.org/10.1016/s1359-6446(01)01755-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Westwell, Andrew. "Novel antitumour molecules." Drug Discovery Today 6, no. 12 (June 2001): 648–49. http://dx.doi.org/10.1016/s1359-6446(01)01829-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 6, no. 13 (July 2001): 699–701. http://dx.doi.org/10.1016/s1359-6446(01)01836-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Westwell, Andrew. "Novel antitumour molecules." Drug Discovery Today 6, no. 17 (September 2001): 916–18. http://dx.doi.org/10.1016/s1359-6446(01)01915-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 7, no. 4 (February 2002): 269–72. http://dx.doi.org/10.1016/s1359-6446(01)02141-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 7, no. 13 (July 2002): 739–40. http://dx.doi.org/10.1016/s1359-6446(02)02311-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 7, no. 14 (July 2002): 780–83. http://dx.doi.org/10.1016/s1359-6446(02)02331-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Tisdale, Michael J. "Antitumour imidazotetrazines—X." Biochemical Pharmacology 35, no. 2 (January 1986): 311–16. http://dx.doi.org/10.1016/0006-2952(86)90531-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Tisdale, Michael J. "Antitumour imidazotetrazines—XV." Biochemical Pharmacology 36, no. 4 (February 1987): 457–62. http://dx.doi.org/10.1016/0006-2952(87)90351-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Bull, Vincent L., and Michael J. Tisdale. "Antitumour imidazotetrazines—XVI." Biochemical Pharmacology 36, no. 19 (October 1987): 3215–20. http://dx.doi.org/10.1016/0006-2952(87)90636-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Tisdale, Michael J. "Antitumour imidazotetrazines—XVIII." Biochemical Pharmacology 38, no. 7 (April 1989): 1097–101. http://dx.doi.org/10.1016/0006-2952(89)90254-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Horgan, Carmel M. T., and Michael J. Tisdale. "Antitumour imidazotetrazines—VIII." Biochemical Pharmacology 34, no. 2 (January 1985): 217–21. http://dx.doi.org/10.1016/0006-2952(85)90127-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Minton, Kirsty. "Enhancing antitumour eosinophils." Nature Reviews Immunology 19, no. 4 (February 20, 2019): 202–3. http://dx.doi.org/10.1038/s41577-019-0142-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Hepburn, Paul A., and Michael J. Tisdale. "Antitumour imidazotetrazines—XXIV." Biochemical Pharmacology 41, no. 3 (February 1991): 339–43. http://dx.doi.org/10.1016/0006-2952(91)90529-e.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Bouma, J., J. H. Beijnen, A. Bult, and W. J. M. Underberg. "Anthracycline antitumour agents." Pharmaceutisch Weekblad Scientific Edition 8, no. 2 (April 1986): 109–33. http://dx.doi.org/10.1007/bf02086146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Westwell, Andrew D. "Novel antitumour agents." Drug Discovery Today 11, no. 23-24 (December 2006): 1122–23. http://dx.doi.org/10.1016/j.drudis.2006.09.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Diel, Ingo J. "Antitumour Effects of Bisphosphonates." Drugs 59, no. 3 (March 2000): 391–99. http://dx.doi.org/10.2165/00003495-200059030-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Bordon, Yvonne. "Antitumour roles for antihistamines." Nature Reviews Immunology 22, no. 1 (December 8, 2021): 4–5. http://dx.doi.org/10.1038/s41577-021-00670-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Gielen, Marcel. "TIN-BASED ANTITUMOUR DRUGS." Main Group Metal Chemistry 17, no. 1-4 (January 1994): 1–8. http://dx.doi.org/10.1515/mgmc.1994.17.1-4.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Carmichael, J. "Antitumour Drug-Radiation Interactions." British Journal of Cancer 65, no. 4 (April 1992): 626. http://dx.doi.org/10.1038/bjc.1992.128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Zitvogel, Laurence, and Guido Kroemer. "Antibodies regulate antitumour immunity." Nature 521, no. 7550 (April 29, 2015): 35–37. http://dx.doi.org/10.1038/nature14388.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Gielen, Marcel. "Tin-based Antitumour Drugs." Metal-Based Drugs 1, no. 2-3 (January 1, 1994): 213–19. http://dx.doi.org/10.1155/mbd.1994.213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Gielen, Marcel. "Tin-based antitumour drugs." Coordination Chemistry Reviews 151 (June 1996): 41–51. http://dx.doi.org/10.1016/s0010-8545(96)90193-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Alcaín, Francisco J., and José M. Villalba. "NQO1-directed antitumour quinones." Expert Opinion on Therapeutic Patents 17, no. 6 (June 2007): 649–65. http://dx.doi.org/10.1517/13543776.17.6.649.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Alderton, Gemma K. "TIM3 suppresses antitumour DCs." Nature Reviews Cancer 12, no. 9 (August 24, 2012): 584. http://dx.doi.org/10.1038/nrc3349.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Everse, K. E., H. Lin, E. L. Stuyt, J. C. Brady, F. Buddingh, and J. Everse. "Antitumour activity of peroxidases." British Journal of Cancer 51, no. 5 (May 1985): 743–46. http://dx.doi.org/10.1038/bjc.1985.113.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Yadav, J. S. "Synthesis of antitumour agents." Pure and Applied Chemistry 65, no. 6 (January 1, 1993): 1349–56. http://dx.doi.org/10.1351/pac199365061349.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Alderton, Gemma K. "TIM3 suppresses antitumour DCs." Nature Reviews Immunology 12, no. 9 (August 24, 2012): 621. http://dx.doi.org/10.1038/nri3288.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Itokawa, Hideji, Hiroshi Morita, Takayoshi Sumitomo, Nobuo Totsuka, and Koichi Takeya. "Antitumour Principles fromAlpinia galanga." Planta Medica 53, no. 01 (February 1987): 32–33. http://dx.doi.org/10.1055/s-2006-962611.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Gielen, M. "Tin-based antitumour drugs." Coordination Chemistry Reviews 151, no. 1 (June 1996): 41–51. http://dx.doi.org/10.1016/0010-8545(95)01216-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Zhang, Ling, Jian-Hui Zhang, and Da-yuan Zhu. "Synthesis, characterisation and antitumour activities of gallic acid hydrazone and its rare earth complexes." Journal of Chemical Research 2008, no. 11 (November 2008): 630–32. http://dx.doi.org/10.3184/030823408x371326.

Full text

Abstract:

A new gallic acid hydrazone, 3,4,5-trihydroxybenzoyl salicylaldehyde hydrazone, and its four rare earth complexes, [LnL (OAc)2] • H2O (Ln = La3+, Sm3+, Tb3+, Dy3+), have been synthesised and characterised on the basis of elemental analyses, molar conductivity, IR and 1H NMR spectra. The antitumour activities of the prepared compounds have also been evaluated. The results indicate that Gallic acid hydrazone and its four complexes synthesised possess antitumour activity to some extent, and the four complexes show higher antitumour activity against the human leukaemia cell line HL-60 than the ligand. The antitumour activity of the gallic acid hydrazone can be improved by the formation of the rare earth complexes.

APA, Harvard, Vancouver, ISO, and other styles

45

Gielen, M., R. Willem, H. Dalil, D. de Vos, C. M. Kuiper, and G. J. Peters. "Toxicity Profiles In Vivo in Mice and Antitumour Activity in Tumour-Bearing Mice of Di- and Triorganotin Compounds." Metal-Based Drugs 5, no. 2 (January 1, 1998): 83–90. http://dx.doi.org/10.1155/mbd.1998.83.

Full text

Abstract:

The in vivo toxicity profiles in mice and the antitumour activity in tumour bearing mice were screened for four di-n-butyltin and five triorganotin carboxylates, di-n-butyltin diterebate (5), bis(phenylacetate) (6), bis(deoxycholate) (7), bis(lithocholate) (8), tri-n-butyltin terebate (9), cinnamate (10), and triphenyltin terebate (11).At their maximum tolerated dosis (MTD), no antitumour effect (T/C ~1) was observed for the compounds 5, 7, 9, 10 and 11. The compounds 6 (T/C = 0.51) and 8 (T/C = 0.42) showed clear antitumour activity after single dose administration and might therefore be of interest for further antitumour activity studies.

APA, Harvard, Vancouver, ISO, and other styles

46

Westwell, Andrew D. "Novel antitumour agents: antitumour activity of potent inhibitors of heat shock protein 90." Drug Discovery Today 12, no. 1-2 (January 2007): 101. http://dx.doi.org/10.1016/j.drudis.2006.11.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Manuaba, Ida Bagus Putra. "SYNTHESIS, IDENTIFICATION AND IN VITRO ANTITUMOUR PRESCREENING TEST OF TRIPHENYLTIN BENZOATE TOWARDS A HUMAN CERVICAL CARCINOMA CELL LINE, HeLa." Indonesian Journal of Chemistry 8, no. 3 (June 20, 2010): 418–22. http://dx.doi.org/10.22146/ijc.21599.

Full text

Abstract:

In this study, triphenyltin benzoate was synthesized first, and followed by antitumor prescreening test of the compound towards a human cervical carcinoma cell line, HeLa. Three reaction steps were employed to obtain the compound needed, i.e. 1) synthesizing of tetraphenyltin compound via insitu phenilmagnesiumbromide Grignard reaction to tin(IV)chloride, 2) synthesizing triphenyltin chloride via redistribution reaction of tetraphenyltin to tin(IV) chloride without any solvent, the reaction completed depends on the temperature, in this case a good results was achieved at temperature 220 °C for 6 h, 3) finally, triphenyltin benzoate was produced through a methathetical reaction of triphenyltin chloride to an excess of sodium benzoate in ethanol. In vitro prescreening antitumour activity of the compound towards a human cervical tumour cell line, HeLa was carried out following an enzyme linked immunosorbent assays (ELISA). By this method, the test ended with good promising results. This indicates by the IC50 of 170 nM which is compared well to cisplatinum with IC50 950 nM. Keywords: redistribution reaction, methathetical reaction, cell line, in vitro, antitumour

APA, Harvard, Vancouver, ISO, and other styles

48

Di GAETANO, Sonia, Giuseppe D'ALESSIO, and Renata PICCOLI. "Second generation antitumour human RNase: significance of its structural and functional features for the mechanism of antitumour action." Biochemical Journal 358, no. 1 (August 8, 2001): 241–47. http://dx.doi.org/10.1042/bj3580241.

Full text

Abstract:

A second generation mutant of dimeric human pancreas RNase (HHP2-RNase), was obtained by a single residue mutation (Glu111 → Gly) of the previously described dimeric human pancreas RNase variant (HHP-RNase). HHP2-RNase was found to be a highly specific antitumour agent, with an enhanced cytotoxic activity compared with HHP-RNase. The structural and functional requisites of the antitumour action of HHP2-RNase were investigated and compared with those of other dimeric antitumour RNases. The stability of the dimeric structure, i.e. the resistance of human dimeric RNase variants to reductive cleavage of the two intersubunit disulphide bonds that bridge the subunits, was determined to be an essential feature of antitumour dimeric RNases. The stability of the dimeric structure is in turn responsible for the resistance to inhibition by the cytosolic RNase inhibitor (cRI). Both the stability of the dimeric structure and the resistance to cRI inhibition appeared to be highly enhanced by an RNase substrate. This suggests a possible role for RNA in the amplification of the antitumour potential of dimeric RNases.

APA, Harvard, Vancouver, ISO, and other styles

49

Takahashi, H. K., and M. Nishibori. "The Antitumour Activities of Statins." Current Oncology 14, no. 6 (December 1, 2007): 246. http://dx.doi.org/10.3747/co.v14i6.153.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Mundell, Ian. "New antitumour drug beats resistance." Inpharma Weekly &NA;, no. 952 (August 1994): 3. http://dx.doi.org/10.2165/00128413-199409520-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!